Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults-Reference-Cited by-同舟云学术

Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults

Published:2024-09-14 Issue:1 Volume:21 Page:
ISSN:1742-4933
Container-title:Immunity & Ageing
language:en
Short-container-title:Immun Ageing

Author:

Gelderloos Anne T.,Verheul Marije K.,Middelhof Irene,de Zeeuw-Brouwer Mary-Lène,van Binnendijk Robert S.,Buisman Anne-Marie,van Kasteren Puck B.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12979-024-00466-9.pdf

Reference45 articles.

1. European Centre for Disease Prevention and Control. Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023 5 April 2023.

2. Rouvinski A, Friedman A, Kirillov S, Attal JH, Kumari S, Fahoum J, et al. Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine. Sci Rep. 2023;13(1):14165.

3. Ravussin A, Robertson AH, Wolf AS, Blix K, Kjonstad IF, Solum G, et al. Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. Lancet Healthy Longev. 2023;4(5):e188–99.

4. Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, et al. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis. 2023;23(8):901–13.

5. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–41.